An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
|
|
Join the Moores Cancer Center (MCC), Work in Progress Seminar Series
Please join MCC's standing Work in Progress Seminar Series every first Wednesday of the month. If you are interested in presenting or joining, then please contact Program Coordinator, Diana Arroyo at d1arroyo@health.ucsd.edu.
|
|
|
Highlights from The Cancer Letter |
Terrance Mayes, Loretta Erhunmwunsee Named Leaders of NCCN Forum on Equity
Read full article on page 16 of The Cancer Letter, volume 49 number 3.
Pancreatic Cancer Survival Edges Up—As Screening Strategies Emerge
Read full article on page 31 of The Cancer Letter, volume 49 number 3.
|
|
|
|
Pharmacology Seminar Series
The LKB1-AMPK Pathway: Central Cell Metabolism and Tumor Suppressor Function
Tuesday, January 31, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
9500 Gilman Drive, La Jolla, CA 92037
Optional Webinar Registration
Reuben J. Shaw, Ph.D.
Professor, Molecular and Cell Biology
Laboratory Director, Salk NCI-Designated Cancer Center
The Salk Institute for Biological Studies
Hosted by Susan Taylor, Ph.D.
Contact: pharmeducation@health.ucsd.edu
|
|
|
|
Pharmacology Seminar Series
Co-organized by the Institute for Diabetes and Metabolic Health and the Cancer Therapeutics (CT2) Training Program
Targeting the Liver Mitochondria to Treat NAFLD/NASH and Cardiometabolic Disease
Monday, February 6, 2023 at 11:00 a.m. PT
Leichtag Biomedical Research Building, Room 107
9500 Gilman Drive, La Jolla, CA 92037
Optional Webinar Registration
Gerald Shulman M.D., Ph.D., MACP, MACE, FRCP
Professor, Molecular and Cell Biology Laboratory
George R. Cowgill Professor of Medicine (Endocrinology) and Professor of Cellular And Molecular Physiology
Co-Director Yale Diabetes Research Center, Internal Medicine
Yale School of Medicine
Hosted by Alan Saltiel, Ph.D., J. Silvio Gutkind, Ph.D., and Dwayne Stupack, Ph.D.
|
|
|
|
DRM Seminar Series
Regenerative Strategies Using mRNA Technology
Monday, February 13, 2023 from 3:00 to 4:00 p.m. PT
Sanford Consortium for Regenerative Medicine
Conference Room 1013 A/B
2880 Torrey Pines Scenic Drive, La Jolla, CA 92037
Zoom Link available upon request.
Panteleimon Rompolas, M.B.A., Ph.D.
Assistant Professor of Dermatology
Department of Dermatology
University of Pennsylvania
Hosted by Shiri Gur-Cohen, Ph.D.
|
|
|
|
Cancer Control Program Work In Progress Seminar Series
Integrating “When to Eat” and “Who Should Eat” and Concepts to Evaluate Inflammatory Foods
Wednesday, March 1, 2023 at 12:00 p.m. PT
MCC Comor Commons Conference Room
Lunch provided, beginning at 11:30 a.m.
Optional Webinar Registration
Tianying Wu, Ph.D.
Associate Professor
San Diego State University, School of Public Health
Division of Epidemiology and Biostatistics
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
|
Vaccination Communication: Inoculating Against Misinformation Q + A
Tuesday, January 31, 2023 at 12:00 p.m. PT
Join us for an exclusive Q + A session on the threat of vaccine mis- and disinformation on social media and the urgency for healthcare organizations and professionals to communicate effectively through social media platforms with trusted messengers. This session is the second part of the webinar the we hosted in December, 2022.
California Immunization Coalition (CIC) is partnering MCC to welcome Todd Wolynn, M.D., MMM and Alex McDonald, M.D., FAAFP, CAQSM.
The Q + A will be moderated by MCC Community Outreach and Engagement staff member Margaux Stack-Babich, M.P.H., and CIC board member Eric Ball, M.D., FAAP, Southern Orange County Pediatric Associates CHOC Children's Primary Care Network.
|
| |
San Diego Colorectal Cancer Screening Roundtable
Thursday, February 22, 2023 from 10:00 a.m. to 12:00 p.m.
Join us for information on the current state of colorectal cancer screening in San Diego, upcoming changes in Medi-Cal, emerging screening tests, and how we can increase screening to get back on track.
This roundtable is designed for medical directors, clinicians, quality improvement staff, panel managers, project managers, and health center staff to hear and share best practices on improving colorectal cancer screenings in San Diego County.
|
|
|
MCC Speed Mentoring Workshop
Thursday, February 9, 2023 at 12:00 p.m. via Zoom
Students, postdocs, and junior faculty are welcome. This virtual workshop lasts for 1 hour, and each trainee (undergraduate, graduate student, medical student, postdoc, resident, fellow, and junior faculty) will have the opportunity to speak with all three mentors. It is a great way to get advice from a variety of perspectives in a short amount of time!
Details and Zoom link will be emailed once registration is completed.
Organized by the MCC Cancer Research Training & Education Coordination (CRTEC) Program
For more information or to sign-up for our monthly Speed Mentor Workshop listserv, please contact Diana Arroyo at d1arroyo@ucsd.edu
|
|
|
Student Volunteers Available
MCC CRTEC has identified three motivated undergraduate students who are interested in volunteering in a lab at MCC. This is a win-win research experience for the students and your lab. Please contact Amy Spilkin, Ph.D. at aspilkin@health.ucsd.edu, if you would like to connect with one or more of these students:
|
- Third-year UCSD undergraduate majoring in Biology, minoring in Math
- Second-year UCSD premed undergraduate majoring in Human Biology
-
First-year UCSD undergraduate majoring in Cognitive and Behavioral Neuroscience
|
CRTEC administration will complete all necessary paperwork for these student volunteers.
|
|
|
Speed Mentoring Workshop, Faculty Sign Ups
Faculty Members of MCC are invited to serve a mentors at the MCC Speed Mentoring Workshops, organized by MCC CRTEC. These workshops serve not only undergraduate, graduate, and post-graduate students, but also project scientists, research scientists, and junior faculty. Please select the session(s) for which are are available to mentor, and please select all that apply. You will be scheduled for only one of the dates that you choose—providing several dates merely helps to coordinate schedules. You will be contacted with a confirmation of the schedule.
CRTEC Speed Mentoring takes place on the second Thursday of each month from 12:00 p.m. to 1:00 p.m. on Zoom. Participating faculty members will receive 1 hour of mentorship credit, approved by MCC leadership.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
The UC Pancreatic Cancer Consortium Plans to Submit a SPORE Proposal to the National Cancer Institute (NCI) in May, 2023
As you may know, SPORE project proposals are distinctly different from either R01 or U01 research mechanisms, in that the proposed projects must be translational. In every SPORE project, the development of new cancer-relevant interventions should include both a laboratory component and a human application (see RFP linked below for further detail). Project budgets are expected on the order of $200,000–$250,000/year for 5 years, although projects on early detection, prevention, or population science can request up to an additional $120,000/year.
Deadline: Tuesday, January 31, 2023
Questions? Contact Kurt Giles, D.Phil. at kurt.giles@ucsf.edu
|
| |
V Foundation 2023 Call for Women Scientists Innovation Award for Cancer Research
Translational Award: a 4-year, $800,000 grant, paid in annual installments.
V Scholar Award: a 3-year, $600,000 grant, paid in annual installments.
MCC is pleased to announce the V Foundation 2023 Call for Women Scientists Innovation Award for Cancer Research. This limited submission request for applications specifically is for women cancer researchers, and applicants may apply for either the Translational or the V Scholar award. This opportunity is restricted to adult cancer research and will fund a range of projects from laboratory-based fundamental research through bench-to-bedside strategies. Research areas not included in this scope for either award are epidemiology, behavioral science, and health services research.
Please note that MCC can nominate ONE candidate for this women cancer researchers call (regardless of award). To be considered for nomination, please send a 1-page letter of intent (LOI) to aballantyne@health.ucsd.edu for review by our grants committee. LOI instructions are directly below; the RFA is attached.
All LOIs must be submitted to Angela Ballantyne, Ph.D .(aballantyne@health.ucsd.edu) in a single PDF by the internal deadline of Monday, February 6, 2023 at 5:00 p.m. Follow these instructions for the submission of your single PDF, which contains both 1 and 2 below:
|
-
Letter of Intent/Research Statement (1 page maximum)
- Arial, at least 11 point font, at least 1/2 inch margins all around, 1 page maximum, including any Figures, Tables, etc. Citations only may be included on a second page.
-
Include your name, degree(s), title, department, phone number, email address; the specific grant to which you are applying (Translational or Scholar), statement of your eligibility per V Foundation guidelines, and project title.
- Briefly describe the nature of the research project, including a brief summary of aims, significance and rationale, preliminary data, and the research plan.
- NIH-style biosketch
- 5 pages max; include active and pending support
- Your LOI submission is NOT complete until you have received Acknowledgment of Receipt.
|
|
|
Limited Submission Opportunity: Mathers Foundation Grant Program
Recent awards have ranged from approximately $300K to $750K total. Indirect costs may not exceed 10%. Grant duration must be 3 years. Universities/Institutions are limited to four applications per cycle.
The mission of the G. Harold and Leila Y. Mathers Foundation is to advance knowledge in the life sciences by sponsoring scientific research that will benefit mankind. Since its inception in 1982, the foundation has granted in excess of $350M. The foundation primarily supports basic science, ideally with potential translational applications. Awards are intended to support the actual investigation and are not intended to be utilized for purchasing capital equipment (“bricks-and-mortar”) for the lab. Budget justifications should provide detailed costs of investigators’ salaries, laboratory supplies, etc., and will be highly scrutinized. The application process is essentially a two-step process, involving a letter of intent (LOI), and if invited, a formal proposal. In general, the entire process may take 90-120 days for the final approval and awarding of a grant.
Areas of interest include immunology, microbiome, genomics, structural biology, cellular physiology, and neuroscience, which are noteworthy examples of current research support.
Projects related to the following areas will not be considered: pre-clinical drug development, drug discovery, clinical trials, COVID-19, medical imaging technology, electrical engineering technology development, plant biology, oceanography, space exploration, and global warming.
Internal Submission Deadline: Wednesday, February 8, 2023 at 5:00 p.m.
Funding Organization's Deadline: Friday, March 31, 2023
|
|
|
Prostate Cancer Foundation (PCF) 2023 Young Investigator Awards Request for Letters of Intent/Full Applications
Award: $75,000 per year for 3 years
The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. For example, this includes funding "protected time" or direct costs for laboratory science. This award does not support indirect costs, such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of one to three mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award.
LOI Deadline: February 10, 2023 by 3:00 p.m. ET
Submission Portal Opens: Monday, February 27, 2023
Invited Full Application Deadline: Monday, April 24, 2023 by 3:00 p.m. ET
Questions? Contact LettersofIntent@pcf.org.
|
|
|
Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
Application budgets may not exceed $500,000 in direct costs per year for the UG3 phase and may not exceed $750,000 in direct costs per year for the UH3 phase
Through this FOA, the NCI intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.
Deadline: February 14, 2023 by 5:00 p.m. and June 14, 2023 by 5:00 p.m.
|
|
|
2023 ACTRI Pilot Projects: Community Research Partnership
These UCSD, Altman Clinical and Translational Research Institute (ACTRI) grants are (1) 1-year competitive awards (up to $30,000) to provide funding for early-stage projects and (2) available to all ACTRI members with faculty appointments; funding priority is given to early-career faculty.
Requests for assistance with identifying potential community or academic partners should be made between October 2022 and November 2022.
Deadline: Friday, February 24, 2023 by 2:00 p.m. PT
|
|
|
University of California, Hematologic Malignancies Consortium (UCHMC) Request for Proposals (RFP)
The UCHMC is requesting submission of proposals within two potential areas of funding: RFP A and RFP B.
All applications are to be submitted via email as a single PDF to Jesika Reiner, M.P.H., M.B.A. at JReiner@uchmc.org and Mwieduwilt@uchmc.org.
RFP A: UCHMC Funds for Junior Faculty and Trainee Competitive Seed Grants
This funding will support single or multi-center pilot clinical trials, translational lab-based projects, or retrospective projects, which may ultimately grow into multi-center UCHMC interventional clinical trials. Funding may be applied for fellowship support to conduct clinical trials research with the UCHMC. Funding also may support correlative research that may or may not be associated with an existing UCHMC trial yet with translational aims that possess potential for development into a UCHMC trial. The award amount will be determined by the UCHMC Steering Committee, but individual requests should not exceed $40,000.
RFP B: UCHMC Funds for Clinical Trials Support
This funding will support underfunded yet promising clinical trials and correlative research projects associated with an existing clinical trials or other multi-center projects that hold promise for development into larger multicenter UCHMC clinical trials. These awards will range from $100,000 to $150,000 in a given award period, with the number of projects awarded based on number of applications and scientific need as determined by the UCHMC Steering Committee, which reserves the right to award a larger total funds as it see fit.
Applicants may apply for both RFPs but will be awarded only one as a lead investigator. An applicant can be a collaborator on more than one application in a given award period.
Application Format
|
- Cover Page
- Project title
- Project investigators (Lead and Sub-Investigators) and affiliations
- Project start date
- Project end date
- Concurrent UCHMC applications of Lead Investigator
- Applicant contact
- Project Information
- Brief project description with hypothesis(es)
- Detailed project description with supporting preclinical and/or clinical data, rationale, study design, and statistical plan, as appropriate
- Budget
- Budget justification
- Other sources of funding
-
Statement of commitment to develop results into UCHMC interventional clinical trials when possible
- Attachments
- CVs of investigators associated with the proposed project
|
|
|
Call for Applications to Fund Travel to Scholarly Meeting for FY 2022/23, Co-infection and Cancer (R01 and R21 Clinical Trial Not Allowed)
Applications may be submitted throughout the year but must be received and approved prior to the conference start date. Applications will be reviewed while funds are available. Funds will not be awarded retroactively.
Any UCSD Health Sciences (HS) Clinical series faculty member holding an M.D. or D.O. can receive one trip every other fiscal year (July 1-June 30). Travel awards (domestic or foreign) will be made for a maximum of $750 toward standard economy airfare and/or registration fees (documentation required).
Eligibility is to HS Clinical series faculty who (1) have an accepted abstract to a scientific professional society conference, (2) are not a member of the Academic Senate, and (3) are either the first or senior author on the abstract podium or poster presentation of original clinical research. Invited lectures, workshops, or panel or moderator invites are ineligible and will not be considered.
|
|
|
Co-infection and Cancer (R01 and R21 Clinical Trial Not Allowed)
R01 Award: Maximum duration is 5 years. For over $500,000/year in direct costs, NIH approval is required.
R21 Award: Combined budget for direct costs for the 2-year maximum project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
The purpose of this FOA is to enhance mechanistic and epidemiologic investigations that address the roles of co-infection and cancer to illuminate presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents—either concurrently or sequentially—and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and co-infections that engender novel opportunities for prevention and treatment.
Deadline: NIH standard submission dates apply.
|
|
|
NCI Program Project Applications for 2023, 2024, and 2025 (P01 Clinical Trial Optional)
Award: Application budgets are not limited yet must reflect the actual needs of the proposed project. The project period may not exceed 5 years.
The purpose of this FOA is to enhance mechanistic and epidemiologic investigations that address the roles of co-infection and cancer to illuminate presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents—either concurrently or sequentially—and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and co-infections that engender novel opportunities for prevention and treatment.
Deadline: NIH standard submission dates apply.
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
Notice of Special Interest (NOSI): Administrative Supplement to Support Global Cancer Stigma Research
This NOSI informs current awardees that the NCI is providing an opportunity for supplemental funding to support exploratory research studies to expand the current understanding of cancer stigma (as defined below), assess its impact on cancer control and prevention, and develop stigma-reduction interventions to improve cancer outcomes in low- and middle-income countries (LMICs).
Applications can be submitted on a rolling basis between January 16, 2023 and May 21, 2023 at 5:00 p.m. local time of applicant organization for FY 2023 funding. Applications for this initiative must be submitted using the following FOA or its subsequent reissued equivalent: PA-20-272
|
|
|
Damon Runyon, Clinical Investigator Award
Award: $600,000 award for 3 years, distributed as $200,000 per year.
Deadline: February 1, 2023 at 4:00 p.m. ET
|
|
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
Maximum budget $375,000 direct costs/year for 5 years; NIH R01 standard due dates apply.
Deadline: February 5, 2023 at 5:00 p.m.
|
|
Coordinating Center for Cannabis and Cannabinoid Use Among Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U24 Clinical Trial Not Allowed)
$500,000 direct costs per year; maximum project period is 5 years.
Deadline: February 17, 2023 at 5:00 p.m. PT
|
|
|
Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)
$500,000 direct costs per year; maximum project period is 5 years.
Deadline: February 18, 2023 at 5:00 p.m. PT
|
|
Notice of Special Interest (NOSI): Administrative Supplement for NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
One CAP-IT Data and Resource Coordination Center will be awarded with a maximum total cost of $800,000 per year (maximum direct cost is $480,000 per year) in fiscal year 2023; at least 1 full year on the parent grant must remain at the time of funding; application budget is limited to 4 years.
Deadline: February 28, 2023
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, U2C Clinical Trial Optional)
Application budgets may not exceed $150,000 in direct costs per year.
Deadline: March 1, 2023 and September 1, 2023
|
|
|
NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
A budget for direct costs of up to $50,000 per year may be requested; maximum project period is 2 years.
Deadline: Standard NIH deadlines apply
|
|
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
The combined budget for direct costs for the 2-year maximum project period may not exceed $275,000; no more than $200,000 may be requested in any single year.
Deadline: Standard NIH deadlines apply
|
| Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Application budgets are not limited but must reflect the actual needs of the proposed project; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
|
|
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Budgets are limited to $600,000 direct costs (excluding consortium F&A) per year; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
| Notice of Special Interest (NOSI): Adaptive Biomaterials for Cancer Biology
This NOSI invites applications that propose the development of advanced biomaterials for use in fundamental cancer biology research and proposals incorporating the novel application of advanced biomaterials to address cancer biology research questions.
Deadline: Standard NIH deadlines apply
|
| |
|
Living with Melanoma Patient Symposium
Saturday, February 4, 2023 from 8:30 a.m. to 12:00 p.m.
University of California, San Francisco, Mission Bay Campus
Arthur and Toni Rembe Rock Hall
1550 4th Street, San Francisco, CA 94158
Hosted by the AIM at Melanoma Foundation and the University of California (UC) Melanoma & Skin Cancer Consortium, this symposium will bring together five of the UC's National Cancer Institute-designated Comprehensive Cancer Centers to share research, clinical trials, and best practices.
|
|
|
Salk T32 Cancer Symposium
Friday, February 10, 2023 from 8:30 a.m. to 5:00 p.m.
Salk Institute, Conrad T. Prebys Auditorium
10010 North Torrey Pines Road
La Jolla, CA 92037
The theme of this year’s symposium is cancer therapeutics. An outstanding lineup of speakers will present on topics that include precision medicine, cancer epigenetics, and immunotherapy. The goal of the symposium is to highlight the amazing research being done by postdocs and students. Those working in cancer biology are encouraged to join attend (deadline: January 27, 2023) and to submit an abstract (deadline: January 9, 2023).
|
|
|
Kyoto University Symposium
Tuesday, February 28, 2023 from 1:00 p.m. to 5:00 p.m.
Roth Auditorium
Sanford Consortium for Regenerative Medicine
|
|
|
| Keynote Speaker
Dr. Shinya Yamanaka
Nobel Laureate in Physiology or Medicine 2012
Director Emeritus and Professor
Department of Life Science Frontiers
Center for iPS Cell Research and Application
Kyoto University
Read More
|
|
|
The symposium will be followed by a reception at the Bella Vista Cafe. Save the date and join us for this unique opportunity to reinvigorate academic collaborations with the prestigious university in Japan.
For more information, please contact Ms. Mariko Adachi, International Strategy Office, Kyoto University at osl.symposium@mail2.adm.kyoto-u.ac.jp
|
|
|
Solid Tumor Therapeutics Program Retreat
Friday, March 3, 2023 from 9:00 a.m. to 4:30 p.m.
UCSD MCC Goldberg Auditorium
The retreat will include catered breakfast and lunch.
|
|
|
Luis Diaz, M.D.
Grayer Family Chair Head, Division of Solid Tumor Oncology Professor, Weill Cornell Medical School
|
|
Lisa Butterfield, Ph.D.
Adjunct Professor of Microbiology and Immunology
University of California, San Francisco
|
|
|
Additional Speakers Include
Sonia Sharma, Ph.D. Anandra W. Goldrath, Ph.D. Liangfang Zhang, Ph.D. Nicole Steinmetz, Ph.D. Shweta Joshi, Ph.D. Tariq Rana, Ph.D. Rebekah White, M.D., FACS Rebecca Shatsky, M.D.
|
|
|
Big Data Training for Cancer Research—BigCare 2023 Summer Workshop
Friday, May 19, 2023 to Sunday, May 28, 2023
Purdue University
West Lafayette, Indiana
There is no cost for registration or tuition for this workshop, which will be held on-site at Purdue University. Moreover, there will be no cost for food or lodging, and travel scholarships will be available for a limited number of participants. Please visit the Purdue University Website for updates.
|
|
|
SHARED RESOURCE SPOTLIGHT
|
|
|
New Community Outreach Partnership with El Centro Regional Medical Center (ECRMC)
On December 15, 2022, the El Centro Regional Medical Center (ECRMC) Multidisciplinary Research Council (MRC) approved a collaborative project with the MCC Biorepository and Tissue Technology Shared Resource (BTTSR), a College of American Pathologists (CAP)-accredited core. This project will support biospecimen procurement at ECRMC, with the main purpose of bridging the gap in the participation in research by populations with health disparities.
For more details, please contact BTTSR at skaushal@health.ucsd.edu
|
|
|
Biostatistics Shared Resource (BSR)
The MCC BSR not only provides comprehensive biostatistics and data analytics collaboration and support, but also is happy to help with grant and protocol development.
The BSR, established in 1995, currently comprises six faculty members and two staff biostatisticians. Together, BSR faculty and staff support best practices in data analysis and statistical inference; reproducible research; clinical trial design, reporting and analysis; causal inference from observational studies; and statistical methodology.
MCC members are not charged for BSR consulting during proposal preparation and early clinical trial protocol development. The BSR's MCC funding is intended for development of long-term collaboration that leads to not only foundation, federal, and industry funding, but also high-profile publications. The BSR also welcomes short consultation requests. Funded projects are expected to incorporate a budget for adequate biostatistics support, which often strengthens grant applications.
The BSR encourages early interaction during proposal planning. For standard proposal development, the BSR needs 4 weeks' advanced notice to review aims, methods, and preliminary results. The BSR can provide not only statistical sections, which include sample size, power calculations, and analysis methods, but also targeted biosketches and letters of support for grant proposals. The BSR recommends contacting the BSR Manager at least 8 weeks in advance for more complex multi-PI, multi-institution, multi-project proposals.
Early interaction during clinical trial development is encouraged. The BSR will provide not only sample size, power calculations, and justifications for any interim safety and/or efficacy analysis, but also randomization plans. During trial operation, the BSR can provide DSMB and regulatory reports, in addition to interim safety and/or final efficacy analysis. The BSR requires negotiated approval of trial budget prior to undertaking these activities.
Please feel free to contact the BSR, which aims to respond within 2 days with a consultation plan. Email Emily Pittman, Ph.D., BSR Manager at eipittman@health.ucsd.edu.
|
|
|
-
Yilmaz E, Ismaila N, Bauman JE, Dabney R, Gan G, Jordan R, Kaufman M, Kirtane K, McBride SM, Old MO, Rooper L, Saba NF, Sheth S, Subramaniam RM, Wise-Draper TM, Wong D, Mell LK (STT). Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers: ASCO guideline. J Clin Oncol. 2022 DEC 15.
- Letellier N, Gutierrez LA, Duchesne J, Chen C, Ilango S, Helmer C, Berr C, Mortamais M, Benmarhnia T (CCP). Air quality improvement and incident dementia: Effects of observed and hypothetical reductions in air pollutant using parametric g-computation. Alzheimers Dement. 2022 DEC 01.
- Eckhardt CM, Gambazza S, Bloomquist TR, De Hoff P, Vuppala A, Vokonas PS, Litonjua AA, Sparrow D, Parvez F, Laurent LC (ZY), Schwartz J, Baccarelli AA, Wu H. Extracellular vesicle-encapsulated microRNAs as novel biomarkers of lung health. Am J Respir Crit Care Med. 2023 JAN 01.
-
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D (HEM), O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Dong J, Adhikary S, et al. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol Oncol. 2022 DEC 10.
|
|
|
To submit any announcements, funding opportunities, events, or other important items to this newsletter, please make use of the newsletter submission form that is linked below.
Please direct any questions that you may have to our Marketing and Communications Coordinator, Sarah Christie at sjchristie@health.ucsd.edu
|
|
|
|
Want to be highlighted in the MCC weekly newsletter or on the MCC website?
We want to know and share in all of our successes at MCC. To that end, we have created a pipeline for our members to share recent publications, awards, new appointments, and research highlights that you would like to see in our MCC weekly newsletter or on the MCC website. Please provide us with the data that we need to showcase your great work by completing the Member Survey linked below.
We sincerely thank you in advance for your time!
|
|
|
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The 360 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and cancer-risk research, MCC investigators address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. Holding Comprehensive status since 2001, MCC was founded in 1977 by John Mendelsohn and received its NCI designation in 1978.
|
|
|
Department of Research Administration
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails. View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|